Imagine Eliminating Wisdom Teeth Extractions with a Non-Surgical Procedure!

TriAgenics is demonstrating the efficacy of our Zero3 Tooth Bud Ablation (TBA) product. We are pre-revenue and have completed pre-production prototype development. We are now scaling manufacturing of our Zero3 TBA product in preparation for applying to the FDA for premarket clearance.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$2,094,248.16 Raised


TriAgenics has developed a solution to a significant problem in the dental industry. Our Zero3 TBA technology offers a minimally invasive, high-precision procedure that is designed to eliminate the need for wisdom teeth removal and the associated pain, cost, and recovery time.

Total U.S. expenditures associated with extracting wisdom teeth and treating wisdom tooth problems are estimated to be more than $3 billion per year. We have calculated our Total Addressable Market (TAM) to be greater than $2.5 billion annually for Zero3 TBA products.*

We have previously raised more than $7.5 million in capital, including Series A1 and A2 preferred stock offerings. TriAgenics has established a solid IP position that includes 13 U.S. patents and a growing number of international patents in Australia, Canada, and Mexico. Our founder is an experienced dentist who has successfully launched 3 startups, which are still in operation today. Our Zero3 TBA technology has grabbed the attention of many oral surgeons and pediatric specialists.

*Information from The National Oral Health Conference (Source
The Total Addressable Market (TAM) calculations were done by TriAgenics based on publicly available data.

the pitch

TriAgenics has developed Zero3 TBA, a minimally invasive dental procedure designed for children ages 6-12 in order to prevent wisdom teeth from ever forming. All R&D is completed with 100% success in preventing tooth formation in animal studies. We are now preparing to apply for FDA 510(k) clearance. Assuming we receive clearance, we then plan to conduct human clinical trials in order to have specific safety data to present before going to market. Our goal is to enter the dental market with first sales in 2024. We have previously raised $7.5 million in capital and have established a solid IP position, including 13 U.S. patents and a growing number of international patents. Our founder is an experienced dentist who has successfully launched 3 startups in the past. Zero3 TBA technology has already garnered interest from oral surgeons and pediatric specialists.


TriAgenics' Zero3 TBA Technology Offers Surgery-Free Prevention of Wisdom Teeth

TriAgenics has developed a technology called Zero3 TBA that has the potential to revolutionize how the dental industry treats wisdom teeth. Zero3 TBA is a minimally invasive procedure designed for kids ages 6-12 in order to prevent wisdom teeth from ever forming. Zero3 TBA will be quick and is expected to have no significant recovery time or significant complications. With a 100% success rate in animal trials, TriAgenics is working to obtain FDA clearance. Assuming that TriAgenics receives clearance, we then plan to conduct human clinical trials in order to have specific safety data to present before going to market. Our goal is to enter the market with first sales in 2024. Our business model is similar to Align Technology’s clear braces. Licensed dentists will send TriAgenics their patients’ x-rays and prescription for Zero3 TBA treatment. TriAgenics will then fabricate custom 3TBA guides and sell them to dentists for an estimated $350 per tooth bud treated. 


Eliminating Wisdom Teeth With Zero3 TBA Technology

Patients underestimate recovery time after having all wisdom teeth extracted. On average, patients miss 2.5 days of work or school because the surgical procedure is highly invasive. When wisdom teeth are allowed to form, they are the most likely teeth to be impacted. This makes them prone to trapping food and bacteria, leading to repeated, expensive treatment later in life. More than 5 million patients in the U.S. spend over $3 billion annually on wisdom teeth extractions or treatments, and more than 80% of all wisdom teeth eventually need to be removed. Zero3 TBA has the potential to prevent the pain, cost, and recovery time associated with wisdom teeth extractions (Source | Source).

We believe Zero3 TBA will deliver better lifelong outcomes for the patient. This minimally invasive treatment is designed to prevent wisdom teeth from ever forming and it is expected to eliminate common complications following wisdom teeth extraction. The treatment takes just 60-90 seconds per tooth bud treated, with the overall procedure estimated at 30 minutes start to finish to treat four tooth buds on one child, and is designed to be easy for dentists to deliver. 

the market & Our Traction

A $2.5 Billion Market Opportunity With Our Advanced Technology


We estimate the total addressable market for TriAgenics’ Zero3 TBA products to be more than $2.5 billion annually. U.S. consumers spend more than $3 billion every year for wisdom tooth extractions and treatment of secondary problems caused by wisdom teeth (Source). More than 80% of wisdom teeth are impacted or do not erupt normally, causing significant dental infections and pain (Source). More than 80% of all wisdom teeth will need to be removed.

We believe TriAgenics is on the brink of revolutionizing dental health with our Zero3 TBA technology. We aim to become the new standard of care for managing wisdom teeth within 10 years of our introduction. Zero3 TBA is a high-precision, minimally invasive procedure designed to eliminate the common complications associated with having wisdom teeth extracted, providing a safer and more effective alternative for kids and parents alike. The fully guided ablation cycle takes just 60 to 90 seconds per tooth bud treated (with the overall procedure estimated at 30 minutes start to finish for four tooth buds) and is designed to be easy for dentists to deliver. Zero3 TBA will be quick and is expected to have no significant recovery time or significant complications. Our founder is an experienced dentist who has successfully launched three startups in the past. We have received positive reactions from dentists, with oral surgeons and pediatric specialists contacting us to learn more about Zero3 TBA.

Why Invest

Disrupting the Wisdom Tooth Extraction Market

Invest in disrupting the wisdom tooth extraction market, where the total addressable market is estimated to be more than $2.5 billion annually. With 93% of all teenagers forming at least one wisdom tooth and over 80% of all wisdom teeth needing to be extracted, the demand for wisdom tooth extractions is significant (Source). Our technology provides an alternative solution for the 5 million patients who spend over $3 billion annually for wisdom tooth extractions and treatment of wisdom tooth problems. 

Join us as we work to revolutionize the dental industry and prevent wisdom teeth from ever forming.


525 SW Umatilla Ave, Suite 102
Redmond, OR 97756

TriAgenics is demonstrating the efficacy of our Zero3 Tooth Bud Ablation (TBA) product. We are pre-revenue and have completed pre-production prototype development. We are now scaling manufacturing of our Zero3 TBA product in preparation for applying to the FDA for premarket clearance.


Leigh Colby
Leigh Colby
President, CEO, Corporate Secretary, and Director
From 1995 through 2015, Leigh was the founder, CEO, and sole shareholder of Oregon Dental Care, a successful group dental practice in Oregon that delivers high-quality patient care in a zero-defect operating environment. In late 2015, Oregon Dental Care was acquired by InterDent, where he served as the Managing Clinical Director. Prior to starting Oregon Dental Care in 1995, Leigh was involved with three high-tech startups that all remain in successful operation today. In 1980, he was the principal founder of Laserdyne Corporation and wrote the ground-breaking specifications for the successful high-resolution Beam Director general-purpose CNC laser machining system. The Beam Director system remains the #1 selling general-purpose laser machining system worldwide. In 1984, he assisted the PhD EE founder of Cyberoptics Corporation in defining their initial product specifications and market applications to establish initial distribution channels for their unique high- resolution, non-contact laser gauging and automated inspection products. Leigh worked with CyberOptics to develop and implement a marketing plan that drove initial product sales and propelled them to a market leader, where they remain today. In 1986, Leigh teamed up with three PhD-level biochemists as their Vice President of Marketing to define and establish their first commercial operations for Surmodics, Inc. His 10-year effort at Surmodics ultimately resulted in revenues approaching $100M annually for the use of PhotoLink high-reliability biocompatibility enhancement technology on a variety of widely recognized implant and disposable medical devices. Surmodics remains a publicly traded operation. Leigh has earned his M.B.A. degree from Northwest Christian University, D.D.S. and B.S. degrees from the University of Minnesota, and B.S. degree from St. John’s University and is a certified Lean Six Sigma Master Black Belt.
David Paul Watson

David Paul Watson

Director & Chief of Operations

Dave brings 25 years of leadership experience to the management team at TriAgenics, Inc. Dave worked for 15 years with IBM in Engineering, Manufacturing, and Product Development, where he held key technical and senior management positions, including critical strategist at IBM Technology Products Division headquarters. He filled the positions of Director of Technology at Planar Systems, Inc., Director of Engineering at Fujitsu Ltd., Director of Manufacturing at Biotronik, Inc., and VP of Engineering at Unilife Medical Solutions, Inc. Dave has patents in the fields of automated equipment and technology products. Dave is the Chief of Operations at TriAgenics, Inc. and is responsible for quality assurance, regulatory affairs, product development, and manufacturing. He holds an MSME from the University of Texas and a BSME from California Polytechnic State University in California.
John Joseph Chopack Jr

John Joseph Chopack Jr

Board Member

John is VP Corporate Development for Neoss Ltd., a dental solutions company headquartered in Europe. He leads all external business development activities, including acquisitions and partnerships. 

Prior to joining Neoss, John was a Principal and founding partner of Inspiros Ventures. John managed the day-to-day operations of Inspiros and was responsible for investment origination, portfolio company management, and investor relations. Johnhas 20 years of experience in private equity/venture capital investing in medtech companies. As a General Partner at HealthpointCapital, a $800 million AUM medtech-focused private equity firm, John played an integral role in the firm’s most profitable investments – Nexa Orthopedics, BioHorizons, and Blue Belt Technologies. These investments brought significant advances to the healthcare field and provided top quartile returns to investors.

Prior to his career in venture capital, John was an orthopedic sales representative for Wright Medical and Encore Orthopedics. Following his experience as an orthopedic sales representative, John worked on Wall Street with Investec and Techvest as a medtech analyst.

John has been recognized as a “40 under 40 Medtech Innovator” by Medical Device and Diagnostic Industry Magazine.

John received a BA from Lafayette College and an MBA from Fordham University Gabelli School of Business.

Jeffrey Miles Jacobs

Jeffrey Miles Jacobs

Board Member

Jeff is the former CEO of Stradis Healthcare, which was acquired in 2021 by Henry Schein, a Fortune 500 Company. He has more than 20 years of experience in the medical device packaging industry.
David Scott Thrower

David Scott Thrower

Board Member

David has more than 30 years of experience with medical device companies,ranging from VP of Marketing for Align Technology (makers of Invisalign) to CEO of several medical device start-ups. He has also served as a Board member of a number of companies, including Aerin Medical, uLab Systems, and Triagenics. David has experience in a wide range of company functions, including sales, marketing, R&D, business development, and manufacturing, for companies with both medical device and consumer applications.
George Shahin

George Shahin

Board Member

George is board-certified in Internal Medicine and Gastroenterology by the American Board of Internal Medicine. He is a member of the American College of Gastroenterology and the American Medical Association. 


Dec. 15, 2023 at 7:59 AM UTC
$15k - $4M
Preferred Stock
Series A-3 Preferred Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

Most Recent Fiscal Year-End

Prior Fiscal Year-End

Total Assets



Cash & Cash Equivalents



Accounts Receivable



Short-Term Debt



Long-Term Debt



Revenue & Sales



Costs of Goods Sold



Taxes Paid



Net Income



*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Investment Incentives and Bonuses*


Friends and Family Early Birds - Invest $25,000+ within the first 72 hours and receive 10% bonus shares

Early Bird Bonus - Invest $1,000 within the first two weeks and receive 5% bonus shares


$25,000+ | Tier 1 - Invest $25,000+ and receive 5% Bonus Shares.

$100,000+ | Tier 2 - Invest $100,000+ and receive 10% Bonus Shares.

Loyalty Bonus:

Existing shareholders of TriAgenics who have expressed interest in making an additional investment in this round and authorized TriAgenics to give their contact information to StartEngine will receive 10% bonus shares.

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

TriAgenics, Inc. will offer 10% additional bonus shares for all investments committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Series A-3 Preferred Stock at $3.00 / share, you will receive 110 Series A-3 Preferred Stock shares, meaning you'll own 110 shares for $300. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the time-based and amount-based bonuses. Eligible investors will also receive the Owner’s Bonus and Loyalty Bonus in addition to the aforementioned bonus.

Irregular Use of Proceeds

The Company will not incur any irregular use of proceeds.



Invest in Disruptive Dental Innovation.

For more than 100 years, dentists have had two choices when it comes to treating your wisdom teeth -- pull them now or treat the problems these troublesome teeth cause later. Both options are traumatic and painful.

TriAgenics' innovative technology solves the problem. Zero3 TBA is a preventive care treatment for kids that prevents wisdom teeth from ever forming. No wisdom teeth. No problems!

Make dentistry feel better. Become a TriAgenics Shareholder today.


Article Image

Investing in the end of wisdom tooth surgery

Article Image

Surgery-free 3rd-molar treatment expected in 2024



Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into TriAgenics.


Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!

Owners bonus

Owner’s Bonus

Owner’s Bonus Members earn 10% bonus shares on top of this and all eligible investments for an entire year. Not a member? Sign up at checkout ($275/year).


Tier 1

Invest $25,000+ and receive 5% Bonus Shares.


Tier 2

Invest $100,000+ and receive 10% Bonus Shares.



James Bickel

a month ago

My son had his wisdom teeth removed four months ago, at age 22. Then this past weekend, he developed an abscess at one of the removal sites. We ended up in the emergency room for hours with CT scans and IV antibiotics. I am in!



Kristin Grau

a month ago

Will the procedure require anesthesia? What is anticipated for the post-procedure course as far as pain, aftercare? What the suspected risks of the procedure? Do you anticipate this being something that requires an oral surgeon or dentist or will it be simple enough that another type of physician may be able to perform the procedure?



Peter Colosimo

a month ago

How are you spending the money? What is your burn rate? How and when do you plan to return investor money, at what rate, how much? How do you plan to address concerns about losing the ability for 3rd molar substitution?



John Houle

2 months ago

As this round of fund raising comes to a close, I would like to commend Dr. Colby and his team. For developing this product and for getting word out about the opportunity. Seeing it on my Instagram feed gives me optimism that, when it is brought to market, it will be promoted well and that will help make its launch very successful.



Bennett Cummins

2 months ago

Is the unit simple to operate as much as a high volume spa could have an add on service to be able to scan a customer if they have a skin lesion and direct them to contact their doctor? Or is the unit require extensive training, customization for skin tone, age, etc? Thanks



Minh Le

2 months ago

How long until you can have revenue generation? What if this is not effective on human? Is there an estimate when the company will be public? $350 per tooth is the cost. How much is the margin to our company?



James Bickel

2 months ago

I saw some discussion / papers back in 2010-2013 of using anesthesia to prevent third molar formation. Could you please comment on this? Was it not effective?



Lisa Sanders

2 months ago

Dr. Colby, how does the 3TBA generator fit into TriAgenics future revenue projections? The business model description in the filing focuses solely on a planned $350/tooth bud charge for the 3TBA guides (and disposable handpiece). However, the generator is described in the same filing as the principal component of the system. Are those generators loaned, leased or sold to dental practitioners? Assuming the generators are in the hands of practitioners for an extended period, how are maintenance and calibration of those units addressed over time? Thank you in advance!



William Reich

2 months ago

Hi I wondered if there were any potential competitors or studies looking at doing ablation by other means. Ex. Using sonic technology - like that used to get rid of kidney stones.. Thanks!



Lisa Sanders

2 months ago

Dr. Colby - I’ve watched your video presentations to the Oregon Biosciences Association in 2020 and Central Oregon Pub Talk in 2021. In both of those presentations you forecasted the start of human trials around the end of 2021. The current information on Start Engine indicates that the application to the FDA for permission to conduct human trials is still pending. Would you please elaborate on the reasons for the delay in applying for / starting human trials? Thank you!




Cancel anytime before 48 hours before a rolling close or the offering end date.



We want you to succeed and get the most out of your money by offering rewards and memberships!


Your info is your info. We take pride in keeping it that way!


Invest in over 200 start-ups and collectibles!


With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


Get To Know Us

Our Team



Important Message

Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA / SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.
By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information

(800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.

The availability of company information does not indicate that the company has endorsed, supports, or otherwise participates with StartEngine.

None of the information displayed on or downloadable from (the any security. It also does not constitute an offer to provide investment advice or service. any security. It also does not constitute an offer to provide investment advice or service. any security. It also does not constitute an offer to provide investment advice or service. StartEngine does not (1) make any recommendations or otherwise advise on the merits or advisability of a particular investment or transaction, or (2) assist in the determination of fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.

All investment opportunities are based on indicated interest from sellers and will need to be confirmed.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks, and you should complete your own independent due diligence regarding the investment. This includes obtaining additional information about the company, opinions, financial projections, and legal or other investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment.

StartEngine Marketplace (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC. (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC. (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC.